Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

NCT01262820 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Pazopanib

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]